A347850 Share Price Performance
₩0
-14000.00 (-100.00%)
Price ₩0
Share Pricen/a
Companies Like D&D Pharmatech (KOSDAQ:347850) Are In A Position To Invest In Growth
Dec 13
D&D Pharmatech Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A347850 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
D&D Pharmatech Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -798.33
- 99.68%
- -415.59%
- 0%
About A347850
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.